Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Padro Arroyo

P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC

Journal of Thoracic Oncology

English

Related publications

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

Journal of Thoracic Oncology

English

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

Journal of Thoracic Oncology

English

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

Journal of Thoracic Oncology

English

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

Journal of Thoracic Oncology

English

P2.01-63 Are Heart Doses Associated With Survival in NSCLC Treated With Post-Operative Radiotherapy? A National Population-Based Study

Journal of Thoracic Oncology

English

P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC

Journal of Thoracic Oncology

English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics

Cancer Research

Oncology

2019

English

Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

English

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Cancer Chemotherapy and Pharmacology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by J. Padro Arroyo

P2.01-37 a Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) With Docetaxel in PTS With Previously Treated NSCLC

Related publications

P2.04-27 Ph II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC

P2.06-09 MiST3: A Phase II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination With Pembrolizumab in PTS With Malignant Mesothelioma

P2.01-34 Prognostic Value of Neutrophil to Lymphocyte Ratio for Metastatic NSCLC Patients Treated With Immunotherapy and Ramucirumab Plus Docetaxel.

P2.13-08 Phase 1 Study of the AXL Inhibitor DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant NSCLC.

P2.01-63 Are Heart Doses Associated With Survival in NSCLC Treated With Post-Operative Radiotherapy? A National Population-Based Study

P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal

Phase II Study of S-1 and Docetaxel for Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer